Alzheimer's disease: The strength of association of costs with different measures of disease severity

Journal of Nutrition, Health and Aging

Volumn 14, Issue 8, 2010, Pages 655-663

  Mauskopf, J ^a   Racketa, J ^b   Sherrill, E ^a  

^a RTI HEALTH SOLUTIONS   (United States)

^b PFIZER INC   (United States)

Author keywords

Alzheimer's disease; behavior; cognition; costs; disease severity; functional status

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; CAREGIVER; COGNITION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; FUNCTIONAL STATUS; HEALTH CARE COST; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

EID: 77957897691     PISSN: 12797707     EISSN: 17604788     Source Type: Journal    
DOI: 10.1007/s12603-010-0312-6     Document Type: Article

References (49)

1. C.W. Zhu M. Sano 2006 Economic considerations in the management of Alzheimer's disease Clin Interv Aging 1 2 143 154 10.2147/ciia.2006.1.2.143 18044111
2. T. Hope J. Keene C.G. Fairburn R. Jacoby R. McShane 1999 Natural history of behavioural changes and psychiatric symptoms in Alzheimer's disease. A longitudinal study Br J Psychiatry 174 39 44 1:STN:280:DyaK1M3islGqtw%3D%3D 10.1192/bjp.174.1.39 10211149 (Pubitemid 29037882)
3. P.J. Neumann R.C. Hermann K.M. Kuntz S.S. Araki S.B. Duff J. Leon P.A. Berenbaum P.A. Goldman M.S. Williams M.C. Weinstein 1999 Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease Neurology 52 6 1138 1145 1:STN:280:DyaK1M3ivFGntQ%3D%3D 10214734
4. B.J. O'Brien R. Goeree M. Hux M. Iskedjian G. Blackhouse M. Gagnon 1999 Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada J Am Geriatr Soc 47 5 570 578 10323651
5. F. Fagnani A. Lafuma M. Pechevis A.S. Rigaud L. Traykov M.L. Seux F. Forette 2004 Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications Dement Geriatr Cogn Disord 17 1-2 5 13 1:CAS:528:DC%2BD3sXpsVKrtLY%3D 10.1159/000074079 14560059 (Pubitemid 37499961)
6. Fenn P, Gray A: Estimating the long term cost savings from treatment of Alzheimer's disease: a modeling approach. Pharmacoeconomics 1999, (2): 165-174.
7. A.B. Hauber A. Gnanasakthy E.H. Snyder M.V. Bala A. Richter J.A. Mauskopf 2000 Potential savings in the cost of caring for patients with Alzheimer's disease: treatment with rivastigmine Pharmacoeconomics 17 4 351 360 1:CAS:528:DC%2BD3cXjtFWrtbc%3D 10.2165/00019053-200017040-00005 10947490 (Pubitemid 30236170)
8. D. Weycker C. Taneja J. Edelsberg M.H. Erder F.A. Schmitt J. Setyawan G. Oster 2007 Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil Curr Med Res Opin 23 5 1187 1197 1:CAS:528:DC%2BD2sXnt1Whu7w%3D 10.1185/030079907X188071 17519086 (Pubitemid 46799603)
9. J.J. Caro D. Getsios K. Migliaccio-Walle G. Raggio A. Ward the AHEAD Study Group 2001 Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care Neurology 57 6 964 971 1:STN:280: DC%2BD3MrisVemsg%3D%3D 11571318
10. J.J. Caro M. Salas A. Ward D. Getsios A. Mehnert the AHEAD Study Group 2002 Assessment of health economics in Alzheimer's Disease. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands Dement Geriatr Cogn Disord 14 2 84 89 1:CAS:528:DC%2BD38Xls1Oru7o%3D 10.1159/000064929 12145455 (Pubitemid 36152949)
11. J. Caro D. Getsios K. Migliaccio-Walle J. Ishak W. El-Hadi the AHEAD Study Group 2003 Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis BMC Geriatr 3 6 10.1186/1471-2318-3-6 14675494
12. C. Green J. Picot E. Loveman A. Takeda J. Kirby A. Clegg 2005 Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease Pharmacoeconomics 23 12 1271 1282 1:CAS:528:DC%2BD28Xot1GitQ%3D%3D 10.2165/00019053-200523120-00010 16336020 (Pubitemid 41803322)
13. C. François H. Sintonen R. Sulkava B. Rive 2004 Cost effectiveness of memantine in moderately severe to severe Alzheimer's disease: a Markov model in Finland Clin Drug Investig 24 7 373 384 10.2165/00044011-200424070-00001 17516724 (Pubitemid 38951789)
14. R.W. Jönes P. McCrone C. Guilhaume 2004 Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective Drugs Aging 21 9 607 620 10.2165/00002512-200421090- 00005 15260515 (Pubitemid 39070995)
15. E. Loveman C. Green J. Kirby A. Takeda J. Picot E. Payne A. Clegg 2006 The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease Health Technol Assess 10 1 iii iv 1:STN:280:DC%2BD28%2Fit1yrsw%3D%3D 16409879
16. Birks J: Cholinesterase inhibitors for Alzheimer's disease [review]. Cochrane Database System Rev 2006, 1. Art. No. CD005593. DOI: 10.1002/14651858.CD005593. (Pubitemid 46841366)
17. P. Raina P. Santaguida A. Ismaila C. Patterson D. Cowan M. Levine L. Booker M. Oremus 2008 Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline Ann Intern Med 148 5 379 397 18316756
18. F. Cortes S. Gillette-Guyonnet F. Nourhashemi C. Christelle B. Vellas 2006 Family history of dementia does not influence the progression of Alzheimer's disease at two years: results from the REAL. FR Study Am J Alzheimers Dis Other Demen 21 2 131 136 10.1177/153331750602100214 16634470
19. P. Behl T.L. Stefurak S.E. Black 2005 Progress in clinical neurosciences: cognitive markers of progression in Alzheimer's disease Can J Neurol Sci 32 2 140 151 16018149
20. A. Bianchetti G.B. Frisoni K.M. Ghisia M. Trabucchi 1998 Clinical predictors of the indirect costs of Alzheimer's disease Arch Neurol 55 130 131 1:STN:280:DyaK1c7gtl2mug%3D%3D 10.1001/archneur.55.1.130 9443721 (Pubitemid 28139116)
21. M. Boada J. Pena-Casanova F. Bermejo F. Guillén W.M. Hart C. Espinosa J. Rovira 1999 Costs of health care resources of ambulatory care patients diagnosed with Alzheimer's disease in Spain Med Clin (Barc) 113 690 695 1:STN:280:DC%2BD3c7hs1emsg%3D%3D
22. N. Herrmann K.L. Lanctôt R. Sambrook N. Lesnikova R. Hébert P. McCracken A. Robillard E. Nguyen 2006 The contribution of neuropsychiatric symptoms to the cost of dementia care Int J Geriatr Psychiatry 21 10 972 976 10.1002/gps.1594 16955429 (Pubitemid 44596392)
23. J. Hill H. Fillit S.K. Thomas S. Chang 2006 Functional impairment, healthcare costs and the prevalence of institutionalization in patients with Alzheimer's disease and other dementias Pharmacoeconomics 24 3 265 280 10.2165/00019053-200624030-00006 16519548 (Pubitemid 43374378)
24. M.J. Hux B.J. O'Brien M. Iskedjian R. Goeree M. Gagnon S. Gauthier 1998 Relation between severity of Alzheimer's disease and costs of caring Can Med Assoc J 159 457 465 1:STN:280:DyaK1cvivFOhsg%3D%3D
25. L. Jönsson P. Lindgren A. Wimo B. Jönsson B. Winblad 1999 Costs of Mini-Mental State Examination-related cognitive impairment Pharmacoeconomics 16 409 416 10.2165/00019053-199916040-00008 10623368 (Pubitemid 29496050)
26. L. Jönsson M.E. Jönhagen L. Kilander H. Soininen M. Hallikainen G. Waldemar H. Nygaard N. Andreasen B. Winblad A. Wimo 2006 Determinants of costs of care for patients with Alzheimer's disease Int J Geriatr Psychiatry 21 449 459 10.1002/gps.1489 16676288
27. I.O. Kang S.Y. Lee S.Y. Kim C.Y. Park 2007 Economic cost of dementia patients according to the limitation of the activities of daily living in Korea Int J Geriatr Psychiatry 22 675 681 10.1002/gps.1729 17171741 (Pubitemid 47180381)
28. S. Kavanagh M. Knapp 1999 Cognitive disability and direct care costs for elderly people Br J Psychiatry 174 S39 S46 10.1192/bjp.174.6.539
29. S. Kavanagh M. Knapp 2002 Costs and cognitive disability: modeling the underlying associations Br J Psychiatry 180 120 125 10.1192/bjp.180.2.120 11823320 (Pubitemid 34142781)
30. C. Kronborg-Andersen J. Segard E. Hansen A. Kragh-Søensen L. Hastrup J. Andersen K. Andersen A. Lolk H. Nielsen P. Kragh-Søensen 1999 The cost of dementia in Denmark: the Odense study Dement Geriatr Cogn Disord 10 295 304 1:STN:280:DyaK1M3psV2iug%3D%3D 10.1159/000017135 10364648 (Pubitemid 29281021)
31. C. Kronborg-Andersen J. Lauridsen K. Andersen P. Kragh-Sorensen 2003 Cost of dementia: impact of disease progression estimated in longitudinal data Scand J Public Health 31 119 125 10.1080/14034940210134059 (Pubitemid 41007524)
32. K.M. Langa M.E. Chernew M.U. Kabeto A.R. Regula Herzog M.B. Ofstedal R.J. Willis R.B. Wallace L.M. Mucha W.L. Straus A.M. Fendrick 2001 National estimates of the quantity and cost of informal caregiving for the elderly with dementia J Gen Intern Med 16 770 778 1:STN:280:DC%2BD3Mnos1elug%3D%3D 10.1111/j.1525-1497.2001.10123.x 11722692
33. J. Leon P.J. Neumann 1999 The cost of Alzheimer's disease in managed care: a crosssectional study Am J Manag Care 5 867 877 1:STN:280: DyaK1MvhsV2nsg%3D%3D 10557408 (Pubitemid 29356812)
34. G. Livingston C. Katona B. Roch C. Guilhaume B. Rive 2004 A dependency model for patients with Alzheimer's disease: its validation and relationship to the costs of care-the LASER-AD study Curr Med Res Opin 20 1007 1016 1:STN:280:DC%2BD2czmt1Wktw%3D%3D 10.1185/030079904125003980 15265245 (Pubitemid 38954463)
35. S. López-Pousa J. Garre-Olmo A. Turon-Estrada F. Hernández I. Expósito M. Lozano-Gallego M. Hernández-Ferrándiz E. Gelada-Batlle I. Pericot-Nierga J. Vilalta-Franch 2004 Cost relation between severity of Alzheimer's disease and cognitive and functional impairment Med Clin (Barc) 122 767 772 10.1157/13062665 (Pubitemid 38923805)
36. M.J. Moore C.W. Zhu E.C. Clipp 2001 Informal costs of dementia care: estimates from the National Longitudinal Caregiver Study J Gerontol B Psychol Sci Soc Sci 56 S219 S228 1:STN:280:DC%2BD3Mzpt1agug%3D%3D 11445614
37. D.L. Murman Q. Chen M.C. Powell S.B. Kuo C.J. Bradley C.C. Colenda 2002 The incremental direct costs associated with behavioral symptoms in AD Neurology 59 1721 1729 1:STN:280:DC%2BD38jhtFyhuw%3D%3D 10.1001/archneur.59.11.1721 12473759 (Pubitemid 35340481)
38. S. Neubauer R. Holle P. Menn M. Grossfeld-Schmitz E. Graesel 2008 Measurement of informal care time in a study of patients with dementia Int Psychogeriatrics 20 1160 1176 10.1017/S1041610208007564
39. G. Nordberg A. Wimo L. Jönsson B.-M. Sjölund M. Lagergren E. von Strauss 2007 Time use and costs of institutionalized elderly person with or without dementia: results from the Nordanstig cohort in the Kungsholmen Project- a population based study in Sweden Int J Geriatr Psychiatry 22 639 648 10.1002/gps.1724 17225239 (Pubitemid 47180376)
40. D.P. Rice P.J. Fox W. Max P.A. Webber D.A. Lindeman W.W. Hauck E. Segura 1993 The economic burden of Alzheimer's disease care Health Aff (Millwood) 12 2 164 176 1:STN:280:DyaK3szoslyksQ%3D%3D 10.1377/hlthaff.12.2.164
41. A.S. Rigaud F. Fagnani C. Bayle F. Latour L. Traykov F. Forette 2003 Patients with Alzheimer's disease living at home in France: costs and consequences of the disease J Geriatri Psychiatry Neurol 16 140 145 10.1177/0891988703252558 (Pubitemid 37409022)
42. G.W. Small D.D. McDonnell R.L. Brooks G. Papadopoulos 2002 The impact of symptom severity on the cost of Alzheimer's disease J Am Geriatr Soc 50 2 321 327 10.1046/j.1532-5415.2002.50065.x 12028215 (Pubitemid 34132433)
43. E. Souetre R.M. Thwaites H.L. Yeardley 1999 Economic impact of Alzheimer's disease in the United Kingdom. Cost of care and disease severity for non-institutionalised patients with Alzheimer's disease Br J Psychiatry 174 51 55 1:STN:280:DyaK1M3islGqtQ%3D%3D 10.1192/bjp.174.1.51 10211151
44. D.H. Taylor M. Schenkman J. Zhou F.A. Sloan 2001 The relative effect of Alzheimer's disease and related dementias, disability, and comorbidities on cost of care for elderly persons J Gerontol 56B S285 S293
45. A. Wimo E. von Strauss G. Nordberg F. Sassi L. Johansson 2002 Time spent on informal and formal care giving for persons with dementia in Sweden Health Policy 61 255 268 10.1016/S0168-8510(02)00010-6 12098519 (Pubitemid 34722779)
46. J. Wolstenholme P. Fenn A. Gray J. Keene R. Jacoby T. Hope 2002 Estimating the relationship between disease progression and cost of care in dementia Br J Psychiatry 181 36 42 1:STN:280:DC%2BD38zmvFaktg%3D%3D 10.1192/bjp.181.1.36 12091261 (Pubitemid 34717836)
47. C.W. Zhu N. Scarmeas R. Torgan M. Albert J. Brandt D. Blacker M. Sano Y. Stern 2006 Longitudinal study of the effects of patient characteristics on direct costs in Alzheimer's disease Neurology 67 998 1005 1:STN:280: DC%2BD28rnt1SjsQ%3D%3D 10.1212/01.wnl.0000230160.13272.1b 16914696 (Pubitemid 44454592)
48. C.W. Zhu C. Leibman T. McLaughlin A.S. Zbrozek N. Scarmeas M. Albert J. Brandt D. Blacker M. Sano Y. Stern 2008 Patient dependence and longitudinal changes in costs of care in Alzheimer's disease Dement Geriatr Cogn Disord 26 416 423 10.1159/000164797 18946219
49. L. Jönsson A. Wimo 2008 The costs of dementia in Europe Pharmacoeconomics 27 391 403 10.2165/00019053-200927050-00004